Bliss GVS Pharma Limited (BLISSGVS) Financial History

Name: Bliss GVS Pharma Limited (BLISSGVS) financial statement history
Creator: TickerBase
License: https://creativecommons.org/licenses/by/4.0/

4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

Healthcare · Drug Manufacturers - Specialty & Generic · DATA UPDATED 2026-09-20

Bliss GVS Pharma Limited (BLISSGVS) operates in the Drug Manufacturers - Specialty & Generic industry and is headquartered in Mumbai, India with about 1,033 employees. Its market capitalization is roughly ₹73 billion. In the fiscal year ended 2026-03-31, BLISSGVS reported ₹9.2B in revenue and ₹1.3B in net income.

Bliss GVS Pharma Limited engages in the development, manufacturing and marketing of pharmaceutical formulations in India and internationally.

Interactive charts & full statements →

BLISSGVS Revenue & Earnings History — Annual Income Statement

Income statement	2026-03-31	2025-03-31	2024-03-31	2023-03-31
Total Revenue	₹9.2B	₹8.0B	₹7.7B	₹7.5B
Gross Profit	₹5.0B	₹3.9B	₹3.8B	₹3.5B
Operating Income (EBIT)	₹1.6B	₹978M	₹1.3B	₹1.0B
Net Income	₹1.3B	₹843M	₹754M	₹709M

INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

BLISSGVS Quarterly Revenue & Earnings — Last 8 Quarters

Quarterly income statement	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30
Total Revenue	₹2.9B	₹2.6B	₹2.2B	₹2.4B	₹2.1B
Gross Profit	₹1.7B	₹1.4B	₹1.2B	₹1.3B	₹1.2B
Operating Income (EBIT)	₹665M	₹358M	₹264M	₹235M	₹331M
Net Income	₹501M	₹356M	₹233M	₹272M	₹430M

INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

BLISSGVS Free Cash Flow History

Cash flow	2026-03-31	2025-03-31	2024-03-31	2023-03-31
Dividends Paid	(₹106M)	(₹54M)	(₹54M)	(₹54M)

INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

BLISSGVS Balance Sheet History

Balance sheet	2026-03-31	2025-03-31	2024-03-31	2023-03-31	2022-03-31
Total Assets	₹14.9B	₹13.0B	₹12.1B	₹11.6B	—
Total Liabilities	₹2.6B	₹2.1B	₹2.1B	₹2.4B	—

INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive BLISSGVS viewer.

Other Companies in Drug Manufacturers - Specialty & Generic

SUVEN · Suven Life Sciences Limited — ₹97 billion
PGHL · Procter & Gamble Health Limited — ₹91 billion
4559 · Zeria Pharmaceutical Co., Ltd. — JPY 89 billion
AARTIPHARM · Aarti Pharmalabs Limited — ₹74 billion
INNOVACAP · Innova Captab Limited — ₹68 billion
MOREPENLAB · Morepen Laboratories Limited — ₹66 billion
4569 · KYORIN Pharmaceutical Co., Ltd. — JPY 65 billion
SPARC · Sun Pharma Advanced Research Company Limited — ₹63 billion

← BLIN All “B” companies BLIV →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.